Product information and disease description Place of product in therapy Disease description Epidemiology

Incidence of Danon disease

3 evidence topics · 5 sources

Incidence and birth prevalence in the general population

No evidence found.

Newborn screening and population screening series

No evidence found.

Nearest measure: share of Danon disease among children with hypertrophic cardiomyopathy

“In fact, the frequency of Danon disease is 4–6% in children with hypertrophic cardiomyopathy” (opens the source at this quote in a new tab)

“However, children sometimes have mutations in lysosome-associated membrane protein 2 (LAMP2; Danon disease) or γ-2 subunit of AMP-activated protein kinase (PRKAG2; cardiac glycogenosis), and their clinical courses and prognoses differ from those of children with sarcomeric HCM.” (opens the source at this quote in a new tab)

Nearest measure: timing of case identification in United States claims, health record, and laboratory data as of July 2026

“Data as of July 2026; over 80% of patients reported in ICD-10 code and genetic testing lab data have been identified in the last 5 years” (opens the source at this quote in a new tab)
“Patients cumulatively identified and include those who received HTx or subsequently experienced disease-related mortality” (opens the source at this quote in a new tab)

Rising case detection with wider availability of LAMP2 testing

“The observed prevalence may be rising due to increased detection from wider availability of LAMP2 testing included in clinical genetic cardiomyopathy gene testing panels.” (opens the source at this quote in a new tab)

“The volume of documented cases is rising with wider availability of genetic testing” (opens the source at this quote in a new tab)